Evidence map›Paper›PMID 27105564›Full record

ReviewVaccine2016

The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps.

Sami L Gottlieb, Carolyn D Deal, Birgitte Giersing, Helen Rees, Gail Bolan, Christine Johnston, Peter Timms, Scott D Gray-Owen, Ann E Jerse, Caroline E Cameron and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Epidemiology ofJournal of global health · 2019
    Pooled it
  11. The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sami L GottliebWorld Health Organization, Geneva, Switzerland. Electronic address: gottliebs@who.int.
Carolyn D DealNational Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Birgitte GiersingWorld Health Organization, Geneva, Switzerland.
Helen ReesWits Reproductive Health and HIV Institute, University of the Witswatersrand, Johannesburg, South Africa.
Gail BolanCenters for Disease Control and Prevention, Atlanta, GA, USA.
Christine JohnstonUniversity of Washington, Seattle, WA, USA.
Peter TimmsUniversity of Sunshine Coast, Queensland Australia and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.
Scott D Gray-OwenUniversity of Toronto, Toronto, ON, Canada.
Ann E JerseUniformed Services University, Bethesda, MD, USA.
Caroline E CameronUniversity of Victoria, Victoria, BC, Canada.
Vasee S MoorthyWorld Health Organization, Geneva, Switzerland.
James KiarieWorld Health Organization, Geneva, Switzerland.
Nathalie BroutetWorld Health Organization, Geneva, Switzerland.

Funding

Extracellular Matrix Adhesins of Treponema pallidumR01AI051334 · NIAID · UNIVERSITY OF WASHINGTON · PI CAMERON, CAROLINE E · 2002 to 2017
$3.4M
Extracellular Matrix Adhesins of Treponema pallidumR37AI051334 · NIAID · UNIVERSITY OF VICTORIA · PI CAROLINE E CAMERON · 2019 to 2026
$2.3M
Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

In 2014, the World Health Organization, the US National Institutes of Health, and global technical partners published a comprehensive roadmap for development of new vaccines against sexually transmitted infections (STIs). Since its publication, progress has been made in several roadmap activities: obtaining better epidemiologic data to establish the public health rationale for STI vaccines, modeling the theoretical impact of future vaccines, advancing basic science research, defining preferred product characteristics for first-generation vaccines, and encouraging investment in STI vaccine development. This article reviews these overarching roadmap activities, provides updates on research and development of individual vaccines against herpes simplex virus, Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, and discusses important next steps to advance the global roadmap for STI vaccine development.

Indexed as

Biomedical ResearchChlamydia InfectionsGonorrheaHerpes SimplexHumansSexually Transmitted DiseasesSyphilisVaccinesVaccinesRoadmapSexually transmitted infectionsSTI vaccine developmentVaccines

Identifiers

PMID27105564
PMCPMC6759054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.